Calcifediol
- TRADE NAME: Rayaldee (Opko)
- INDICATIONS: Hyperparathyroidism in stage 3 or 4 chronic kidney disease
- SYNONYM: calcidiol
- CLASS: Vitamin D analog
- HALF-LIFE: 11 days
FDA APPROVAL DATE: 06/17/2016
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Anticonvulsants, Atazanavir, Cholestyramine, Clarithromycin, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Ritonavir, Saquinavir, Telithromycin, Thiazides, Voriconazole
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric